Vectura Wins US GSK Patent Litigation and Awarded $89.7Million in Damages by Trial Jury
Vectura Group plc (LSE:VEC) ("Vectura" or "the Group") confirms that on 3rd May 2019 following a jury trial in the United States District Court for the District of Delaware, the relevant asserted claim of Vectura’s US patent 8303991 was found valid and infringed by US sales of three of GlaxoSmithKline’s (GSK) Ellipta products. The jury awarded Vectura $89.7m in damages for the period from August 2016 through December 2018, based on a calculation of 3% of US sales of these products. Vectura expects to seek application of the 3% royalty to the sales of the infringing products through the end of the patent term in mid-2021. The jury also found that GSK’s infringement was willful. The willfulness finding gives Vectura the right to seek enhanced damages. GSK has the option to appeal the decision.
James Ward-Lilley, Chief Executive Officer of Vectura, commented:
“Although we regret the need to take a longstanding partner to court, we are pleased with the jury’s verdict which confirms the validity of our intellectual property and the decision to progress this action with GSK. We will provide updates on this matter in due course.”
Background to litigation:
In July 2016, Vectura filed a patent infringement lawsuit against GSK in the United States District Court for the District of Delaware claiming that sales of certain GSK Ellipta products infringed Vectura patents.
Vectura and GSK had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family. These licensed patents expired in July 2016. At this time GSK had the option to license additional patent families under the original agreement but declined to do so, resulting in the filing of the lawsuit by Vectura.
From the outset Vectura has been open to finding a mutually acceptable solution to avoid prolonging the dispute. Those efforts were not fruitful and led to the litigation progressing to a jury trial in April 2019.
Expected news flow for 2019
In the meantime, we continue to focus on executing our strategy and to build on our recently reported strong financial and operational progress. Further expected news flow for 2019 includes:
- VR315 (US) repeat clinical study read-out and resubmission
- VR647 (US) partnering post FDA end of Phase II meeting
- Updated disclosure on new nebulised niche portfolio assets, including potential orphan drug designation
- QVM149 Phase III study completion and submission
This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products, and through the development of high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at www.vectura.com
Vectura Group plc
David Ginivan – VP Corporate Communications
+44 (0)7471 352 720
Elizabeth Knowles – VP Investor Relations
+44 (0)7767 160 565
Consilium Strategic Communications
+44 (0)7739 788 014
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
STALICLA Appoints Stéphane Baudouin as Chief of Science17.10.2019 22:01:00 CEST | Press release
STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant Research Scientist at Greenwood Genetic Center (SC, USA). STALICLA will pursue its collaboration with the Greenwood Genetic Center, which is a leading translational research center in genetics and neurodevelopmental disorders, including ASD. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005803/en/ STALICLA's Chief of Science - Stéphane Baudouin (Photo: STALICLA) Dr. Baudouin is a neurobiologist with extensive research experience in the pathophysiology of Autism Spectrum Disorder. His previous work focused on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions. Before joining STALICLA, Stéphane was a Senior
Laser System Partnership Sets Sights on Ending Toll Road Delays17.10.2019 22:00:00 CEST | Press release
A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics. Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions. Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.
IFF to Release Third Quarter 2019 Results November 417.10.2019 20:15:00 CEST | Press release
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced that it will release its third quarter 2019 earnings results following the market close on Monday, November 4, 2019. The management team will host a live webcast on Tuesday, November 5, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.co
PTC Launches Global Event Series with FT Live to Help Industrial Enterprises Embrace Digital Transformation17.10.2019 18:00:00 CEST | Press release
PTC (NASDAQ: PTC) today announced the launch of Digital Transformation: The New Reality World Tour, a new event program that extends the excitement of the annual PTC LiveWorx® event. The new event program features the debut of the FT-PTC Future of Industrial Innovation Global Series, produced with FT Live, the global events arm of the Financial Times. As a component of The New Reality World Tour program, this insightful series will empower leaders of industrial companies to achieve success with their digital transformation strategies. According to McKinsey & Company, more than 70% of large-scale digital transformation efforts are likely to fail due to a lack of executive sponsorship, imprecise business cases, and delayed technology implementation. The New Reality World Tour program guides stakeholders of all levels, from the C-suite to the frontline worker, through these potential hurdles, enabling industrial enterprises to succeed with digital transformation. “The New Reality World To
Pioneer Cement of UAE to Develop US$200 Million Greenfield Cement Project in Georgia17.10.2019 17:49:00 CEST | Press release
The UAE based Pioneer Cement Industries (“Pioneer Cement”), part of Oman based Raysut Cement Company SAOG (RCC) is in the process of setting up a 1.2 m tonnes per annum capacity integrated cement plant in Georgia, Eastern Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005812/en/ Mr. Joey Ghose, RCC Group CEO (Photo : AETOSWire) Pioneer Cement owns concession to limestone mines in Georgia that will provide the key raw materials to this project. Georgia provides Pioneer Cement an opportunity to diversify from the Middle East into a market with large infrastructure growth and shortage of clinker and high-quality cement, the company said in a statement. The plant will be located near Tbilisi, adjacent to the limestone mines. The debt and equity arrangements for the project are currently being finalized and the construction work in the project is slated to commence from Q4 2019. The value of the project is estimated
Bermuda Premier Announces Commitment to Digital Currencies at Tech Summit17.10.2019 17:40:00 CEST | Press release
Premier David Burt officially opened the Bermuda Tech Summit yesterday and announced the country would begin accepting 1:1 U.S. dollar-backed digital currencies for the payment of government taxes, fees and services as part of its efforts to ensure Bermuda continues to lead the development of the global fintech industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005802/en/ The keynote conversation between Bermuda Premier David Burt and Circle CEO Jeremy Allaire, moderated by Jessel Mendes, BDA Board Member and Partner at EY (Photo: Business Wire) Throughout the day, more than 300 attendees, a third of whom travelled to Bermuda from overseas, heard from an impressive array of expert speakers who discussed the transformational impact of technology on investment and business models in a wide range of industry sectors relevant to Bermuda. The Bermuda Business Development Agency (BDA) hosted the free-to-attend summit,